GLPG2737 + Placebo
Phase 2Terminated 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Autosomal Dominant Polycystic Kidney Disease
Conditions
Autosomal Dominant Polycystic Kidney Disease
Trial Timeline
Nov 10, 2020 → Apr 4, 2023
NCT ID
NCT04578548About GLPG2737 + Placebo
GLPG2737 + Placebo is a phase 2 stage product being developed by Galapagos for Autosomal Dominant Polycystic Kidney Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT04578548. Target conditions include Autosomal Dominant Polycystic Kidney Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04578548 | Phase 2 | Terminated |
| NCT03474042 | Phase 2 | Completed |
Competing Products
19 competing products in Autosomal Dominant Polycystic Kidney Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ABBV-CLS-628 + Placebo | AbbVie | Phase 2 | 52 |
| AZD1613 - Part A + Placebo - Part A + AZD1613 - Part B + Placebo - Part B | AstraZeneca | Phase 1 | 33 |
| Placebo + Everolimus | Novartis | Approved | 85 |
| Octreotide + Placebo | Novartis | Phase 2/3 | 65 |
| Everolimus + Calcineurin inhibitors maintenance | Novartis | Phase 3 | 77 |
| Bosutinib + Bosutinib + Placebo | Pfizer | Phase 2 | 51 |
| VX-407 | Vertex Pharmaceuticals | Phase 2 | 51 |
| VX-407 + LNG/EE + NGM/EE + NET/EE + DRSP/EE | Vertex Pharmaceuticals | Phase 1 | 32 |
| VX-407 + Placebo + Midazolam + VX-407 | Vertex Pharmaceuticals | Phase 1 | 32 |
| VX-407 + Placebo | Vertex Pharmaceuticals | Phase 1 | 32 |
| Tesevatinib | Sanofi | Phase 1/2 | 40 |
| Tesevatinib + Placebo | Sanofi | Phase 2 | 51 |
| Venglustat + Placebo | Sanofi | Phase 2/3 | 64 |
| Bardoxolone methyl oral capsule + Placebo oral capsule | Biogen | Phase 3 | 74 |
| Lanreotide + saline | Ipsen | Phase 3 | 74 |
| KB105 | Krystal Biotech | Phase 2 | 49 |
| KB105 | Krystal Biotech | Phase 1/2 | 38 |
| Lixivaptan + Placebo | Centessa Pharmaceuticals | Phase 3 | 72 |
| QR-1123 | ProQR | Phase 1/2 | 33 |